The latest market pricing of acotinib/acalabrutinib in 2024

Acalabrutinib/Acalabrutinib is a therapeutic drug for patients with mantle cell lymphoma (MCL) who have been treated with other chemotherapy drugs. It can also be used alone or in combination with obinutuzumab for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). As a kinase inhibitor, acotinib inhibits the proliferation of cancer cells by blocking the function of abnormal proteins, thereby preventing the spread of cancer.

Acotinib is taken in the form of oral capsules. Patients are usually recommended to take it every 12 hours, either with or without meals. It is important that patients follow their doctor's instructions, take the medication on time and in the correct amount, and ensure that the capsule is swallowed whole to ensure the best effect of the medication.

In China, the original drug acotinib has been launched and included in medical insurance, reducing the financial burden on patients. Common medicines with 100 mg, 8 pills and 7 plates have a market price of about RMB 40,000 or more. However, in the international market, the price of this original drug may soar to more than 10,000 US dollars (the price may fluctuate due to exchange rates), which is a heavy burden for many patients.

Thankfully, generic drugs of acotinib are currently on the market, and these generic drugs are highly similar to the original drug in terms of active ingredients. For example, the market price of 100mg*60 pills produced by a pharmaceutical company in Laos is only more than 3,000 yuan (the price may be adjusted due to exchange rate changes), providing patients with a more economical and affordable treatment option.